Bufadienolides preferentially inhibit aminopeptidase N among mammalian metallo-aminopeptidases; relationship with effects on human melanoma MeWo cells

Bufadienolides are steroids that inhibit Na+/K+-ATPase; recent evidence shows that bufalin inhibits the activity of porcine aminopeptidase N (pAPN). We evaluated the selectivity of some bufadienolides on metallo-aminopeptidases. Among the enzymes of the M1 and M17 families, pAPN and porcine aminopep...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of biological macromolecules 2023-02, Vol.229, p.825-837
Hauptverfasser: Pascual Alonso, Isel, Rivera Méndez, Laura, Almeida García, Fabiola, Valdés-Tresanco, Mario Ernesto, Alonso Bosch, Roberto, Perera, Wilmer H., Arrebola Sánchez, Yarini, Bergado, Gretchen, Sánchez Ramírez, Belinda, Charli, Jean-Louis
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Bufadienolides are steroids that inhibit Na+/K+-ATPase; recent evidence shows that bufalin inhibits the activity of porcine aminopeptidase N (pAPN). We evaluated the selectivity of some bufadienolides on metallo-aminopeptidases. Among the enzymes of the M1 and M17 families, pAPN and porcine aminopeptidase A (pAPA) were the only targets of some bufadienolides. ѱ-bufarenogin, telocinobufagin, marinobufagin, bufalin, cinobufagin, and bufogenin inhibited the activity of pAPN in a dose-dependent manner in the range of 10−7–10−6 M. The inhibition mechanism was classical reversible noncompetitive for telocinobufagin, bufalin and cinobufagin. Bufogenin had the lowest Ki value and a non-competitive behavior. pAPA activity was inhibited by ѱ-bufarenogin, cinobufagin, and bufogenin, with a classical competitive type of inhibition. The models of enzyme-inhibitor complexes agreed with the non-competitive type of inhibition of pAPN by telocinobufagin, bufalin, cinobufagin, and bufogenin. Since APN is a target in cancer therapy, we tested the effect of bufadienolides on the MeWo APN+ human melanoma cell line; they induced cell death, but we obtained scant evidence that inhibition of APN contributed to their effect. Thus, APN is a selective target of some bufadienolides, and we suggest that inhibition of APN activity by bufadienolides is not a major contributor to their antiproliferative properties in MeWo cells. •Telocinobufagin, marinobufagin, bufalin, cinobufagin and bufogenin inhibited pAPN through a noncompetitive mechanism.•Docking studies suggest that these molecules interacted with the S1 and S1´ sites of pAPN without chelation of zinc ion.•ѱ-bufarenogin, cinobufagin, and bufogenin, also inhibited pAPA with a classical competitive type of inhibition.•Bufadienolides and bestatin reduced human melanoma MeWo cell line viability/metabolism and increased cell death.•Some bufadienolides modified the percentages of MeWo cells in each cell cycle phase and/or cells with DNA fragmentation.
ISSN:0141-8130
1879-0003
DOI:10.1016/j.ijbiomac.2022.12.280